P I Industries Ltd Q2 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Published 7 Aug 2026 | Fertilizers & Agrochemicals | Market Cap: ₹42.6K Cr
Biologicals business is a global long-term play currently in the investment phase with ~$12 million revenue; expected to grow at a high rate over next 2-3 years before profitability improves. Biologicals business is in the investment phase with current revenue around $12 million; high growth expected over next 2-3 years with focus on scaling rather than margins now; profitability to follow as scale improves (Rajnish Sarna, p.18).
From P I Industries Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.
Price
₹2,497
Market Cap
₹42.6K Cr
P/E Ratio
35.5
How does P I Industries Ltd rank in Fertilizers & Agrochemicals?
Compare P I Industries Ltd against every Fertilizers & Agrochemicals company this quarter on revenue, margins and earnings-call signals.
P I Industries Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹1.6K Cr, net profit ₹200 Cr.
Full financials →📊 Revenue & Sales Performance
- →Biologicals business is a global long-term play currently in the investment phase with ~$12 million revenue; expected to grow at a high rate over next 2-3 years before profitability improves.
- →Biologicals have been growing at double-digit rates and expected to continue as a key growth driver over next 5-10 years.
- →Pharma business showed 54% Y-o-Y growth in H1 FY26; despite biotech funding slowdown, long-term positive outlook with capability building ongoing.
- →AgChem exports experienced volume-led decline but new products grew 38% Y-o-Y in H1 FY26; 8-10 new molecules planned for commercialization this fiscal.
- →Domestic business impacted by erratic rainfall and regulatory changes but expected positive trajectory in H2, especially with improved Rabi season outlook.
- →Overall industry demand expected to normalize and recover by Q4 FY26 with gradual normalization of inventories.
- →Long-term growth outlook remains intact, focusing on sustainable expansion across Ag Sciences, Pharma CRDMO, Specialty Chemicals, and biologicals.
📈 Profitability & Margins
- →Biologicals business is in the investment phase with current revenue around $12 million; high growth expected over next 2-3 years with focus on scaling rather than margins now; profitability to follow as scale improves (Rajnish Sarna, p.18).
- →Pharma segment is also in investment phase; profitability expected to materialize after 1 year as scale builds (Rajnish Sarna, p.12).
- →CSM (Custom Synthesis & Manufacturing) segment faces softness in H1 FY26 but recovery expected from Q4 FY26; growth potentially single-digit in second half but full recovery not before H2 2026 or later (Rajnish Sarna & Mayank Singhal, pp.16,7).
- →Overall, short-term headwinds exist due to climatic and market conditions; however, medium to long-term growth outlook remains positive with expectation to regain momentum in coming years (Mayank Singhal & Sanjay Agarwal, pp.6,4).
- →EBITDA margins to remain resilient with annual margin guidance maintained despite short-term variability (Mayank Singhal, p.9).
🏗️ Capital Expenditure Plans
- →The company is actively investing in its Pharma CRDMO platform, focusing on capability-building, people, processes, and planned upgrades/additions to assets to support strategic growth.
- →In electronic chemicals, there are two dedicated plants: one near commissioning and another multi-product plant, indicating ongoing capex in this segment.
- →Biologicals business is currently in the investment phase, including market and product development across the US, Brazil, Europe, Mexico, and India, along with commissioning a new biological research center in Hyderabad.
- →The company is evaluating several inorganic opportunities domestically and internationally but is cautious due to market uncertainties and is willing to hold cash while seeking the right opportunities.
- →No specific quantitative capex figures were disclosed for these investments.
💰 Fundraising & Capital Structure
- →The company currently has a strong cash position and is not in a hurry to deploy available cash.
- →They are actively evaluating several inorganic opportunities domestically and internationally, including technology areas outside India.
- →There is no specific mention of planned fundraising through debt or equity in the near term.
- →The company prefers to sit on cash and wait for the right set of opportunities rather than raising funds immediately.
📋 Order Book & Pipeline
- →The current overall order book position stands at approximately $1.25 billion as of Q2 FY26.
- →The company does not provide order book guidance broken down by specific fiscal years (e.g., FY26 or FY27).
- →Demand normalization and inventory destocking in the global agrochemical industry are expected to improve order flow visibility from Q4 FY26.
- →The management anticipates a recovery and positive growth trajectory in the second half of calendar year 2026.
- →Order book growth is tied to market normalization and customer delivery schedules, with expectations of recovery over the next 2-3 quarters.
- →No specific order book size forecast for FY27 is provided currently, as it remains too early for clear guidance.
Key Metrics
Frequently Asked Questions
What were P I Industries Ltd Q2 FY26 results?
Biologicals business is a global long-term play currently in the investment phase with ~$12 million revenue; expected to grow at a high rate over next 2-3 years before profitability improves. Biologicals business is in the investment phase with current revenue around $12 million; high growth expected over next 2-3 years with focus on scaling rather than margins now; profitability to follow as scale improves (Rajnish Sarna, p.18).
What is P I Industries Ltd share price analysis?
P I Industries Ltd currently shows a neutral. The stock trades at a P/E of 35.5 with a market cap of ₹42,633 Cr. Investors should review the full earnings analysis for detailed insights.
Is P I Industries Ltd planning capital expenditure?
The company is actively investing in its Pharma CRDMO platform, focusing on capability-building, people, processes, and planned upgrades/additions to assets to support strategic growth.
Keep P I Industries Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.